170 related articles for article (PubMed ID: 36823043)
1. FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance.
Wang Z; Shen J; Chen C; Wen T; Li C
Biosci Trends; 2023 May; 17(2):136-147. PubMed ID: 36823043
[TBL] [Abstract][Full Text] [Related]
2. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib.
Zhao Z; Song J; Zhang D; Wu F; Tu J; Ji J
Life Sci; 2021 Jan; 264():118642. PubMed ID: 33148422
[TBL] [Abstract][Full Text] [Related]
3. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
[TBL] [Abstract][Full Text] [Related]
4. SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway.
Fan M; Chen Z; Shao W; Chen Y; Lin Z; Yi C; Li Y; Lu L; Zhou Y; Lin J
Acta Biochim Biophys Sin (Shanghai); 2023 Jul; 55(9):1479-1486. PubMed ID: 37434430
[TBL] [Abstract][Full Text] [Related]
5. SOX18 Affects Cell Viability, Migration, Invasiveness, and Apoptosis in Hepatocellular Carcinoma (HCC) Cells by Participating in Epithelial-to-Mesenchymal Transition (EMT) Progression and Adenosine Monophosphate Activated Protein Kinase (AMPK)/Mammalian Target of Rapamycin (mTOR).
Sun Y; Lei B; Huang Q
Med Sci Monit; 2019 Aug; 25():6244-6254. PubMed ID: 31427562
[TBL] [Abstract][Full Text] [Related]
6. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
7. O-GlcNAcylation promotes the migratory ability of hepatocellular carcinoma cells via regulating FOXA2 stability and transcriptional activity.
Huang H; Wu Q; Guo X; Huang T; Xie X; Wang L; Liu Y; Shi L; Li W; Zhang J; Liu Y
J Cell Physiol; 2021 Nov; 236(11):7491-7503. PubMed ID: 33843053
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer.
Xian L; Zhao P; Chen X; Wei Z; Ji H; Zhao J; Liu W; Li Z; Liu D; Han X; Qian Y; Dong H; Zhou X; Fan J; Zhu X; Yin J; Tan X; Jiang D; Yu H; Cao G
Cell Oncol (Dordr); 2022 Oct; 45(5):1019-1036. PubMed ID: 36036881
[TBL] [Abstract][Full Text] [Related]
10. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
11. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.
Shi Z; Liu R; Lu Q; Zeng Z; Liu Y; Zhao J; Liu X; Li L; Huang H; Yao Y; Huang D; Xu Q
Int J Med Sci; 2021; 18(16):3749-3758. PubMed ID: 34790050
[TBL] [Abstract][Full Text] [Related]
12. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
[No Abstract] [Full Text] [Related]
13. USP22-JMJD8 axis promotes Lenvatinib resistance in hepatocellular carcinoma.
Guo J; Zhao J
Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119617. PubMed ID: 37898375
[TBL] [Abstract][Full Text] [Related]
14. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.
Wang Y; Tan K; Hu W; Hou Y; Yang G
Exp Cell Res; 2022 Nov; 420(1):113335. PubMed ID: 36084669
[TBL] [Abstract][Full Text] [Related]
15. Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma.
Yen CH; Lu YC; Li CH; Lee CM; Chen CY; Cheng MY; Huang SF; Chen KF; Cheng AL; Liao LY; Lee YH; Chen YM
Mol Med; 2012 Mar; 18(1):286-96. PubMed ID: 22160218
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.
Zheng L; Yang W; Wu F; Wang C; Yu L; Tang L; Qiu B; Li Y; Guo L; Wu M; Feng G; Zou D; Wang H
Clin Cancer Res; 2013 Oct; 19(19):5372-80. PubMed ID: 23942093
[TBL] [Abstract][Full Text] [Related]
17. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
[TBL] [Abstract][Full Text] [Related]
18. Opposing Roles of the Forkhead Box Factors FoxM1 and FoxA2 in Liver Cancer.
Chand V; Pandey A; Kopanja D; Guzman G; Raychaudhuri P
Mol Cancer Res; 2019 May; 17(5):1063-1074. PubMed ID: 30814128
[TBL] [Abstract][Full Text] [Related]
19. Focal adhesion kinase confers lenvatinib resistance in hepatocellular carcinoma via the regulation of lysine-deficient kinase 1.
Hou W; Gad SA; Ding X; Dhanarajan A; Qiu W
Mol Carcinog; 2024 Jan; 63(1):173-189. PubMed ID: 37787401
[TBL] [Abstract][Full Text] [Related]
20. [Research advances in the mammalian target of rapamycin signaling pathway and its inhibitors in treatment of hepatocellular carcinoma].
Li SZ; Xu F; Sun CQ; Xu P
Zhonghua Gan Zang Bing Za Zhi; 2018 Jan; 26(1):77-80. PubMed ID: 29804369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
